Similar articles for PMID: 38307556

Year	Number of Results
2011	1
2012	1
2013	3
2014	8
2015	10
2016	10
2017	14
2018	13
2019	14
2020	13
2021	14
2022	10
2023	11
2024	2
2025	0

1

Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.

Sakamoto S, Ando K, Pae S, Zhao X, Sakai K, Sato K, Saito S, Yamada Y, Rii J, Goto Y, Sazuka T, Imamura Y, Anzai N, Akakura K, Nishio K, Ichikawa T. Sakamoto S, et al. Anticancer Res. 2024 Feb;44(2):639-647. doi: 10.21873/anticanres.16853. Anticancer Res. 2024. PMID: 38307556

2

Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.

Kubota Y, Hatakeyama S, Yoneyama T, Yoneyama MS, Hamano I, Konishi S, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Kubota Y, et al. World J Urol. 2021 Sep;39(9):3265-3271. doi: 10.1007/s00345-021-03649-x. Epub 2021 Mar 6. World J Urol. 2021. PMID: 33675416

3

Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U. Lolli C, et al. Prostate. 2019 Aug;79(11):1211-1220. doi: 10.1002/pros.23804. Prostate. 2019. PMID: 31251826

4

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341. JAMA Oncol. 2015. PMID: 26181238 Free PMC article.

5

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM. Seitz AK, et al. Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14. Eur Urol. 2017. PMID: 28818355

6

AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.

Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K. Okegawa T, et al. Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5. Prostate. 2018. PMID: 29508425

7

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.

Del Re M, Conteduca V, Crucitta S, Gurioli G, Casadei C, Restante G, Schepisi G, Lolli C, Cucchiara F, Danesi R, De Giorgi U. Del Re M, et al. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):524-531. doi: 10.1038/s41391-020-00309-w. Epub 2021 Jan 26. Prostate Cancer Prostatic Dis. 2021. PMID: 33500577 Free PMC article.

8

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

Salvi S, Casadio V, Conteduca V, Lolli C, Gurioli G, Martignano F, Schepisi G, Testoni S, Scarpi E, Amadori D, Calistri D, Attard G, De Giorgi U. Salvi S, et al. Oncotarget. 2016 Jun 21;7(25):37839-37845. doi: 10.18632/oncotarget.9341. Oncotarget. 2016. PMID: 27191887 Free PMC article.

9

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, Rossi L, Carretta E, Masini C, Amadori D, Calistri D, Attard G, De Giorgi U. Salvi S, et al. Br J Cancer. 2015 May 12;112(10):1717-24. doi: 10.1038/bjc.2015.128. Epub 2015 Apr 21. Br J Cancer. 2015. PMID: 25897673 Free PMC article.

10

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.

Fernandez-Perez MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, Font A, Vázquez-Estévez S, González-Del-Alba A, Wetterskog D, Antonarakis ES, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez Sanchez A, Santander C, Sáez MI, Puente J, Tudela J, Martínez A, López-Andreo MJ, Padilla J, Lozano R, Hervas D, Luo J, de Giorgi U, Castellano D, Attard G, Grande E, Gonzalez-Billalabeitia E. Fernandez-Perez MP, et al. Prostate. 2023 Mar;83(4):376-384. doi: 10.1002/pros.24469. Epub 2022 Dec 23. Prostate. 2023. PMID: 36564933 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 38307556

98 results

Results by year